What is the translation of " ROTATEQ " in English?

• rotateq

Examples of using Rotateq in Croatian and their translations into English

Kako čuvati RotaTeq.
How to store RotaTeq.

RotaTeq sadrži saharozu.
RotaTeq contains sucrose.

Kako primjenjivati RotaTeq.
How to use RotaTeq.

RotaTeq s hranom i pićem.
RotaTeq with food and drink.

Drugi lijekovi i RotaTeq.
Other medicines and RotaTeq.

Kako je RotaTeq ispitivan?
How has RotaTeq been studied?

RotaTeq je namijenjen isključivo dojenčadi.
RotaTeq is intended for use in infants only.

Zašto je RotaTeq odobren?
Why has RotaTeq been approved?

RotaTeq je cjepivo koje se primjenjuje oralno.
RotaTeq is a vaccine that is taken by mouth.

Razina zaštite koju osigurava RotaTeq temelji se na primjeni sve 3 doze cjepiva.
The level of protection provided by RotaTeq is based on the completion of all 3 doses.

RotaTeq je dostupan u pakiranjima s 1 ili 10 tuba za doziranje.
RotaTeq is available in pack size of 1, 10 dosing tubes.

U kliničkim ispitivanjima te nakon stavljanja lijeka u promet prijavljene su sljedeće nuspojave povezane s primjenom RotaTeq cjepiva.
The following side effects were reported in clinical studies or during marketed use with RotaTeq.

Kako RotaTeq izgleda i sadržaj pakiranja.
What RotaTeq looks like and contents of the pack.

Ako je Vaše dijete već bilo zaraženo rotavirusom, ali se u vrijeme cijepljenja još nije razboljelo, RotaTeq ga možda neće zaštititi od bolesti.
If your child has already been infected with rotavirus but is not yet ill when vaccinated, RotaTeq may not be able to prevent the illness.

RotaTeq treba primijeniti odmah nakon vađenja iz hladnjaka.
RotaTeq should be administered promptly after removal from refrigeration.

Ako liječnik smatra da bi takvo dojenče bilo pod većim rizikom ako ne primi cjepivo, treba razmotriti primjenu RotaTeq cjepiva uz mjere opreza.
Administration of RotaTeq may be considered with caution in such infants when, in the opinion of the physician, withholding the vaccine entails a greater risk.

RotaTeq sadrži viruse koji nose antigene za neke vrste rotavirusa koje se najčešće pojavljuju.
RotaTeq contains viruses that carry the antigens for some of the most commonly occurring types of rotaviruses.

U velikom opservacijskom ispitivanju praćenja sigurnosti nakon stavljanja u promet nije primijećen povećan rizik od Kawasakijeve bolesti u dojenčadi koja su primila RotaTeq vidjeti dio 5.1.
No increased risk of Kawasaki disease was observed among infants receiving RotaTeq in a large post- marketing observational safety surveillance study see section 5.1.

RotaTeq se može dati prijevremeno rođenoj dojenčadi ako su rođena nakon navršenog 25. tjedna trudnoće.
RotaTeq may be given to infants who were born early provided that the pregnancy had lasted at least 25 weeks.

Što morate znati prije nego Vaše dijete primi RotaTeq Nemojte primjenjivati RotaTeq: ako je Vaše dijete alergično na bilo koji sastojak cjepiva pogledajte dio 6.
What you need to know before your child receives RotaTeq Do not use RotaTeq if: your child is allergic to any of the components of this vaccine(see section 6Contents of the pack and other information). your child developed an allergic reaction after receiving a dose of RotaTeq or other rotavirus vaccine.

RotaTeq se može davati prerano rođenoj dojenčadi pod uvjetom da je razdoblje gestacije trajalo najmanje 25 tjedana.
RotaTeq may be given to infants who were born prematurely provided that the period of gestation was at least 25 weeks.

Nadalje, rizik od ove nuspojave nije bio statistički značajno povećan tijekom prvih 0-30 dana praćenja u usporedbi s onim u kontrolnoj skupini dojenčadi koja je u tom razdoblju primila DTaP, ali ne i RotaTeq n=62 617, 12 339osoba- godina praćenja.
In addition, there was no statistically significant increased risk of this adverse event during the 0-30 day follow-up period compared with a concurrent control group of infants who received DTaP, but not RotaTeq n=62,617, 12,339 person-years of follow-up.

Nije poznat opseg zaštite koju RotaTeq može pružiti protiv drugih tipova rotavirusa i u drugih populacijskih skupina.
The extent of protection that RotaTeq might provide against other rotavirus types and in other populations is unknown.

RotaTeq se u ispitivanjima izlučio u stolici u 8,9% primatelja cjepiva, gotovo isključivo u prvom tjednu od primitka prve doze te samo u jednog primatelja(0,3%) nakon treće doze cjepiva.
In trials, RotaTeq was shed in the stools of 8.9% of vaccine recipients almost exclusively in the week after dose 1 and in only one vaccine recipient(0.3%) after dose 3.

Na temelju zbirnih podataka dobivenih iz 3 klinička ispitivanja u kojima je 6130 dojenčadi primalo RotaTeq, a 5560 placebo, navedene nuspojave bile su od 0,2% do 2,5% češće zabilježene u primatelja cjepiva RotaTeq nego u primatelja placeba.
Based on pooled data from 3 clinical trials in which 6,130 infants received RotaTeq and 5,560 received placebo, the adverse reactions listed occurred with excess incidences in RotaTeq recipients compared to placebo recipients of between 0.2% and 2.5.

RotaTeq je indiciran za aktivnu imunizaciju dojenčadi u dobi od 6 tjedana do 32 tjedna radi prevencije gastroenteritisa uzrokovanog infekcijom rotavirusom vidjeti dijelove 4.2, 4.4 i 5.1.
RotaTeq is indicated for the active immunisation of infants from the age of 6 weeks to 32 weeks for prevention of gastroenteritis due to rotavirus infection see sections 4.2, 4.4 and 5.1.

Primi li Vaše dijete prvu dozu RotaTeq cjepiva, preporučuje se da do kraja cijepljenja također prima RotaTeq a ne neko drugo cjepivo protiv rotavirusa.
When RotaTeq is given to your child for the first dose, it is recommended that your child also receives RotaTeq(and not another rotavirus vaccine) to complete the vaccination course.

RotaTeq se mora s oprezom primjenjivati u osoba koje su u bliskom kontaktu s imunodeficijentnim osobama npr. osobama s malignim bolestima ili drugim imunokompromitiranim osobama ili osobama koje primaju imunosupresivnu terapiju.
RotaTeq should be administered with caution to individuals with close contacts who are immunodeficient e.g., individuals with malignancies or who are otherwise immunocompromised or individuals receiving immunosuppressive therapy.

Pokazalo se da, u usporedbi sa zasebnom primjenom, istodobna primjena cjepiva RotaTeq s cjepivima DTaP-IPV-HBV-Hib(Infanrix hexa) u dojenčadi u dobi od približno 2, 3 i 4 mjeseca ne utječe na imunološki odgovor i profile sigurnosti tih istodobno primijenjenih cjepiva.
Co-administration of RotaTeq with DTaP-IPV-HBV-Hib vaccine(Infanrix hexa) at approximately 2, 3, and 4 months of age demonstrated that the immune responses and the safety profiles of the co-administered vaccines were unaffected compared to separate administrations.

RotaTeq se ne smije primjenjivati u djece koja su preosjetljiva(alergična) na djelatnu tvar ili bilo koji drugi sastojak cjepiva ili u djece koja su pokazala znakove alergije nakon primanja doze cjepiva RotaTeq ili nekog drugog cjepiva protiv rotavirusa u prošlosti.
RotaTeq must not be used in babies who are hypersensitive(allergic) to the active substance or any of the other ingredients, or who showed signs of allergy after receiving a dose of RotaTeq or another vaccine against rotavirus in the past.